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Cisplatin, a standard chemotherapeutic agent for many
tumors, has an unfortunately common toxicity where almost
a third of patients develop renal dysfunction after a single
dose. Acute kidney injury caused by cisplatin depends on
Fas-mediated apoptosis driven by Fas ligand (FasL) expressed
on tubular epithelial and infiltrating immune cells. Since the
role of FasL in T cells is known, we investigated whether its
presence in primary kidney cells is needed for its toxic effect.
We found that all cisplatin-treated wild-type (wt) mice died
within 6 days; however, severe combined immunodeficiency
(SCID)/beige mice (B-, T-, and natural killer-cell-deficient)
displayed a significant survival benefit, with only 55%
mortality while exhibiting significant renal failure. Treating
SCID/beige mice with MFL3, a FasL-blocking monoclonal
antibody, completely restored survival after an otherwise
lethal cisplatin dose, suggesting another source of FasL
besides immune cells. Freshly isolated primary tubule
segments from wt mice were co-incubated with thick
ascending limb (TAL) segments freshly isolated from mice
expressing the green fluorescent protein (GFP) transgene
(same genetic background) to determine whether FasL-
mediated killing of tubular cells is an autocrine or paracrine
mechanism. Cisplatin-stimulated primary segments induced
apoptosis in the GFP-tagged TAL cells, an effect blocked
by MFL3. Thus, our study shows that cisplatin-induced
nephropathy is mediated through FasL, functionally
expressed on tubular cells that are capable of inducing
death of cells of adjacent tubules.
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The incidence of acute kidney injury (AKI) has recently been
shown to be significantly higher than previously estimated
in a population-based study.1 AKI is associated with high
mortality rates and the need for renal replacement therapy.
Apoptosis appears to have an important role in the patho-
physiology of prerenal, intrarenal, and postrenal failure.2
In general, apoptosis is mediated through receptor-mediated
extrinsic and mitochondria-involving intrinsic pathways.3
Therefore, receptors that mediate apoptosis or intracellular
molecules involved in the extrinsic or intrinsic pathways are
therapeutic targets in AKI.
Fas ligand (FasL, CD95L, CD178, Apo-1L, TNFSF6,
APT1LG1) is a 281 amino acid type II transmembrane
protein of the tumor necrosis factor (TNF) family of
receptors. Its best-characterized function is the induction
of apoptosis of target cells via the default receptor Fas.3
FasL is predominantly expressed by natural killer (NK) cells
and activated T lymphocytes that undergo activation-
induced cell death. In activation-induced cell death,
T lymphocytes induce ‘fratricide’ in other T lymphocytes,
a mechanism required for the termination of immune
responses.3 In T lymphocytes and NK-cells, FasL is
stored safely intracellularly in secretory lysosomes. These
lytic granules contain soluble pro-apoptotic perforins and
granzymes, and FasL as a transmembrane component. Upon
T-cell receptor stimulation, preformed secretory lysosomes
fuse with the plasma membrane to release their death-
inducing load into the intercellular junction.4,5 Shortly
after its appearance on the cell surface, FasL is shed from
the membrane by the matrix metalloprotease ADAM10.6,7
Besides immune cells, FasL has been reported to be expressed
in the epithelial cells of the eye, testis, uterus and placenta,
thyrocytes, lung, CD68þ histiocytes of the dermis, and
intervertebral discs (reviewed in5,8), rendering these tissues
immune-privileged regions. In the kidney, mesangial cells,
tubular epithelial cells, renal fibroblasts, and renal endothelial
cells have been suggested to express FasL.9,10 In contrast to
the detailed data available for FasL expression on immune
cells, the functional relevance of FasL expression on renal
cells has not yet been demonstrated.
The chemotherapeutic drug cisplatin is part of a standard
combined chemotherapy for a variety of malignancies,
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including ovarian, testicular, head and neck, and lung
cancers.11 Because B30% of treated patients develop signs
of renal dysfunction after a single application of cisplatin,12
nephrotoxicity is one of the most recognized adverse events.
Currently, no standard procedure can preserve the remaining
kidney function, especially in cases where patients request to
discontinue the therapy because of side effects and in cases of
cisplatin overdose.13,14 In our experiments, cisplatin serves as
a model substance for the induction of apoptosis in renal
tubular cells and acute toxic renal failure. Tsuruya et al.15
demonstrated survival advantages for cisplatin-treated Fas-
mutated lpr-mice and TNFR1-knockout mice compared with
wild-type (wt) mice. RNA-interference targeting Fas has been
reported to protect mice against renal ischemia/reperfusion
injury.16 The role of FasL in the pathophysiology of cisplatin-
induced acute renal failure has been controversial. When FasL
was cloned in 1993, its expression was described in the lymph
nodes, small intestine, lung, and testis, but not in the
kidney.17 On the one hand, the apoptotic stimulus is
mediated through FasL, at least in part, by infiltrating
T lymphocytes, as demonstrated by Liu et al.18 because
depletion of CD4þ or CD8þ T cells protected mice from
lethal cisplatin-induced nephropathy (CIN). On the other
hand, FasL on the surface of kidney cells might also have a
role in the complex pathophysiological course of CIN, which
remains only partially understood.19
Here, we show that blocking FasL with the monoclonal
antibody MFL3, which has successfully been used to inhibit
murine FasL in spinal cord injury,20 reduces CIN and
prolongs survival after otherwise lethal cisplatin doses. We
demonstrate prolonged survival of severe combined immu-
nodeficiency (SCID)/beige mice that lack B and T lympho-
cytes and NK-cells. However, complete survival following
CIN required the SCID/beige phenotype and, additionally, a
blockade of FasL by MFL3. Because lymphocytes or NK-cells
cannot be responsible for FasL-mediated kidney damage in
this setting, we analyzed cisplatin-induced apoptosis in
freshly isolated thick ascending limb (TAL) segments. For
the first time, this study provides evidence that primary
tubular cells are able to commit FasL-mediated fratricide in
primary isolated TAL segments in the complete absence of
immune cells, highlighting the functional relevance of FasL
on tubular cells.
RESULTS
Application of the anti-FasL monoclonal antibody MFL3
prevents cisplatin-induced deterioration of kidney function
To investigate the overall contribution of FasL to acute
cisplatin-mediated renal failure, 6–8-week-old male C57/B6N
mice were treated with intraperitoneal (i.p.) injections of
vehicle, with 20mg cisplatin per kg body weight alone or in
combination with a single application of 200 mg of the FasL-
blocking monoclonal antibody MFL3. Blood samples were
taken 2 days after injection to estimate AKI by analyzing
concentrations of serum urea (Figure 1a) and serum
creatinine (Figure 1b). The application of MFL3 significantly
reduced the cisplatin-mediated increase in serum urea
(Po0.02, n¼ 10) and serum creatinine (Po0.02, n¼ 10).
MFL3 prevents structural damage and apoptosis caused
by CIN
Periodic acid-Schiff staining of kidneys taken from cisplatin-
treated mice shows severe acute tubular necrosis within 24 h
after i.p. application of 20mg cisplatin per kg body weight
(Figure 1c). Structural kidney damage was significantly
reduced by simultaneous injection of MFL3 in a dose-
dependent manner. Of two investigated doses of MFL3, both
significantly reduced the renal damage score (50 mg: Po0.02;
200 mg: Po0.001; Figure 1d). Immunohistochemistry for
cleaved caspase-3 reveals high levels of apoptotic nuclei in
cisplatin-treated mice when compared with vehicle-treated
mice. A significant reduction in apoptotic nuclei, with only
sporadic appearance of cells positively stained for cleaved
caspase-3, was seen in mice treated with cisplatin plus MFL3
(Figure 1e). The number of apoptotic cells, as determined by
active caspase-3 immunohistochemistry, was significantly reduced
in mice treated with both cisplatin and MFL3 compared with
cisplatin-treated mice (Figure 1f; Po0.02, n¼ 8).
MFL3 restores survival after otherwise lethal CIN
in a dose-dependent manner
To investigate a putative survival benefit to MFL3-treated animals,
we administered an i.p. injection of phosphate-buffered saline
Figure 1 |Application of the Fas ligand (FasL)-blocking antibody MFL3 protects mice from cisplatin-induced acute renal failure.
6–8-week-old male C57/B6N mice received an i.p. injection of vehicle (phosphate-buffered saline) only or 20mg cisplatin per kg body
weight alone or in combination with 200mg MFL3. At 2 days after injection, blood samples were analyzed for serum urea (a) and serum
creatinine (b). Blood levels of vehicle-treated animals are depicted on the left bar of each picture. MFL3 potently reduces the cisplatin-
mediated increases of both parameters (Po0.02, n¼ 10). Tubular damage of representative kidneys taken 24 h after vehicle treatment (left),
cisplatin injection (middle), or cisplatin plus 200 mg MLF3 (right) is demonstrated. Panel c shows periodic acid-Schiff staining with severe
acute tubular necrosis in cisplatin only-treated mice (middle) compared with MFL3 co-treated mice (right) and vehicle-treated controls (left).
These histopathological changes were quantified using renal damage scores (d). Both 50mg MFL3 and 200 mg MFL3 significantly reduced
renal damage scores *Po0.02; **Po0.001. Panel e demonstrates immunohistochemical staining for activated caspase-3 with numerous
apoptotic cells in the cisplatin-treated animals (middle) compared with slight morphological changes including only single apoptotic cell in
animals treated with cisplatin plus MLF3 (right) or vehicle-treated mice (left). Bar¼ 50mm. Quantification of cleaved caspase-3 is
demonstrated in panel f, where positive cells were counted per cross-section, demonstrating a significant prevention of cisplatin-mediated
apoptosis after application of MFL3 (Po0.02). Survival rates of mice after an otherwise lethal CIN increase in a dose-dependent manner after
additional application of MFL3 (g). Cisplatin-treated mice received intraperitoneal injections of vehicle (open rings), 200 mg of isotype
control antibody (open triangles), 10 mg MFL3 (black dots), 50mg MFL3 (black triangles), or 200ml MFL3 (black squares).
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(PBS), cisplatin alone, cisplatin plus isotype control anti-
body, or cisplatin plus MFL3 to C57/B6N mice. As depicted
in Figure 1g, three different concentrations of MFL3 were
investigated (10 mg (black dots), 50 mg (black triangles), or
200 mg (black squares), n¼ 9 for each group). All vehicle-
treated mice (rings) and isotype control antibody-treated
mice (open triangles) died before day 5.5. At day 8.5, one
mouse (11.1%) survived in the 10 mg MFL3 group, two mice
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(22.2%, Po0.05) survived in the 50 mg MFL3 group, and a
55.6% survival rate (five out of nine mice, Po0.001) was
seen for mice that received 200 mg MFL3 in combination
with cisplatin.
SCID/beige mice exhibit marked renal failure after
otherwise lethal CIN
To analyze the in vivo relevance of FasL on infiltrating T and
NK cells in the course of CIN, we compared survival rates of
mice after i.p. injection of 20mg cisplatin per kg body weight
in C57/B6N (wt) mice and immunodeficient SCID/beige
mice. All cisplatin-treated wt mice died before day 5.5. At this
time, all SCID/beige mice were alive, although characterized
by reduced activity. Therefore, blood was taken at day 5.5 and
the SCID/beige mice were killed. Interestingly, the analyses of
serum urea and serum creatinine concentrations from all
SCID/beige mice suggested severe renal failure (Figures 2a
and b; n¼ 9). Interestingly, structural kidney damage in
SCID/beige mice 5.5 days after injection of 20mg cisplatin
per kg body weight could be prevented by additional
treatment with 200 mg MFL3 (Figure 2c and d). Concomi-
tantly, the number of terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL)-positive cells was reduced
from 53.3% (±9.4%) in cisplatin-treated SCID/beige to
10.4% (±5.9%) in cisplatin plus MFL3-treated SCID/beige
mice (Figure 2e and f).
Blocking FasL completely protects SCID/beige mice from
otherwise lethal CIN
Analyzing long-term survival, all wt mice died before day 5.5,
and five out of nine SCID/beige mice died between days 6.5
and 10.5. Interestingly, all SCID/beige mice that additionally
received a single dose of 200 mg MFL3 were completely
protected from lethality for more than 3 months (Figure 2g;
Po0.001). This experiment demonstrates a functional role of
non-T- and non-NK-cell-borne FasL in the course of acute
toxic renal failure, highlighting the functional relevance of
kidney cell-expressed FasL.
FasL expressed by renal TAL cells executes cell death
after cisplatin stimulation
To further investigate the role of FasL in tubular cells, we
incubated freshly isolated segments of the TAL segments from
C57/B6N mice with 100 mg/ml cisplatin alone, 100 mg/ml
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Figure 2 |Blocking Fas ligand (FasL) reduces kidney damage and mortality of severe combined immunodeficiency (SCID)/beige mice in
CIN. Urea (a) and creatinine (b) serum concentrations from SCID/beige mice were taken at day 5.5 after injection of vehicle or 20mg cisplatin
per kg body weight (n¼ 9). Hematoxylin and eosin–stained kidney micrographs taken from SCID/beige mice at day 5.5 after injection of vehicle,
20mg cisplatin per kg body weight alone, or cisplatin plus 200mg MFL3 (c). Histopathological changes were quantified using renal damage
scores (d). 40,6-diamidino-2-phenylindole (DAPI), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and merge of
kidney sections taken from SCID/beige mice at day 5.5 after injection of vehicle, cisplatin alone, or cisplatin plus MFL3 (e) were counted and
statistically analyzed in (f). Survival rates of wild-type (wt) mice compared with SCID/beige mice treated with and without MFL3 after induction
of otherwise lethal CIN. Wt mice (open triangles) and SCID/beige mice received 20mg cisplatin per kg body weight. SCID/beige mice
additionally received either vehicle (open rings) or 200mg MFL3 (black triangle), respectively (g) (n¼ 9). *Po0.02.
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cisplatin plus 10 mg/ml MFL3, or vehicle (PBS). After 4 h of
incubation at 37 1C, TAL segments were subjected to
cytospins and stained for TUNEL-positivity. No apoptosis
was seen in vehicle- or MFL3-treated TAL segments, whereas
cisplatin-incubated segments exhibited significant TUNEL-
positive staining (Figure 3a). A total of 500 40,6-diamidino-
2-phenylindole-positive cells were counted for each group
and TUNEL-positivity was quantified. Baseline apoptosis
rates in vehicle- and MFL3-treated TAL segments were 2.5
and 1.5%, respectively. MFL3 co-incubation reduced the
number of cisplatin-mediated apoptotic cells from 42.5 to
10.0% (Po0.002; Figure 3b). In the complete absence of
immune cells, this experiment demonstrates that tubular
cells induce apoptosis via endogenously produced FasL
ex vivo.
FasL expressed by cisplatin-stimulated murine renal
primary tubular segments (PTCs) executes fratricide
in primary TAL segments ex vivo
In order to distinguish whether FasL-mediated killing of
tubular cells is an autocrine or paracrine mechanism, we
co-incubated freshly isolated primary tubular segments (PTCs)
from C57/B6N mice with TAL segments, freshly isolated from
green fluorescent protein (GFP)-transgenic mice of the same
background. Figure 4a shows a co-culture approach of wt
PTCs with GFP-TAL segments. First, PTCs were incubated
with PBS or 100 mg/ml cisplatin to induce FasL-mediated
apoptosis. After 4 h of stimulation at 37 1C, these tubules
were treated for 20min with 1 mg/ml collagenase IV and
washed three times in PBS in order to wash out cisplatin and
break up the tubular compartment, and to gain single cell
suspension of apoptotic cells. Second, the cisplatin-stimu-
lated PTCs or PBS-treated PTCs were subsequently co-incu-
bated for further 6 h with freshly isolated naı¨ve GFP-TAL
segments (not cisplatin exposed) that have been pre-treated
with collagenase IV for 3min in the presence or absence of
10 mg/ml MFL3, and subjected to cytospins. Figure 4b shows
fluorescence of GFP-TAL segments (green), 40,6-diamidino-
2-phenylindole (blue) and TUNEL-staining (red) as well as
GFP/TUNEL overlay. In all, 500 cells from GFP-TAL segments
of each group were counted and analyzed for TUNEL-
positivity. Percentages of GFP-TUNEL double-positive cells
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were depicted in Figure 4c. GFP-TAL segments that exhibited
TUNEL-positivity were identified as ‘apoptotic by fratricide’.
In the cisplatin-PTC-treated group, the percentage of
fratricidal GFP-TUNEL double-positive cells was reduced in
the presence of MFL3 from 23.3 to 4.7% (Po0.001).
Control-PTCs and MFL3-treated control-PTCs showed no
significant TUNEL-positivity (o2.2%).
DISCUSSION
The effect of the Fas-FasL pro-apoptotic pathway on toxic
acute renal failure as studied in Fas-receptor mutated lpr-
mice, which showed slight protection against acute toxic
renal failure and the attenuation of CIN in TNF-receptor
knockout mice, first described a role of TNF family members
in the context of CIN.15 In the following studies, the
pathophysiological role of infiltrating immune cells has been
demonstrated in either CD4- or CD8-deficient mice.18 Before
10 years, several reports suggested the expression of FasL in
mesangial cells, tubular epithelial cells, renal fibroblasts, and
renal endothelial cells, as reviewed by Ortiz et al.10 Even
though, at least for renal tubular cells, the expression of FasL
has been shown at the mRNA and protein levels and on the
cell surface in primary tubular cell cultures,9 the functional
relevance of kidney-borne endogenous FasL has remained
elusive, whereas the pathophysiological role of infiltrating
immune cells has been partially proven.
Acute renal failure, as induced by cisplatin, leads to the
generation of danger signals by tubular cells, resulting in
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Figure 3 | Fas ligand (FasL)-mediated apoptosis in primary isolated murine thick ascending limb (TAL) segments in the absence
of immune cells. Segments of the TAL from C57/B6N mice were isolated and incubated with vehicle or vehicle plus 10 mg/ml MFL3
only, 100 mg/ml cisplatin alone, or 100mg/ml cisplatin plus MFL3 for 4 h at 37 1C, and were stained for terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL)-positivity (a). Whereas nuclei from cisplatin-incubated TAL segments exhibited 42.5% TUNEL-positivity,
MFL3 co-incubation reduced TUNEL-positivity to 10.0% (b). *Po0.05.
Figure 4 |Cisplatin-induced Fas ligand (FasL)-mediated ‘fratricide’ in freshly isolated primary tubular segments. Primary tubular
segments (PTCs) were isolated from C57/B6N mice and incubated at 37 1C for 4 h with phosphate-buffered saline or 100 mg/ml cisplatin
to generate cells that undergo apoptosis. To analyze whether these stimulated PTCs are capable of inducing apoptosis in tubular cells,
thick ascending limb (TAL) segments, freshly isolated from green fluorescent protein (GFP)-transgenic mice (GFP-TAL segments), were
added. Before 6 h of incubation with or without 10 mg/ml MFL3, an aliquot was immediately removed for cytospin-preparation. PTCs
and GFP-TAL segments are distinguished as shown in (a). After the incubation period, the approaches were subjected to cytospins and
stained for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positivity. GFP-TAL segments (green), nuclei (blue),
and apoptotic cells (red) are illustrated in (b). To quantify cells from GFP-TAL segments that have been caused to undergo apoptosis by
PTCs, a GFP-TUNEL overlay is demonstrated. TUNEL-positive cells from GFP-TAL segments of each group were counted in a double-blind
manner. Representative results of three independent experiments are shown in (c). GFP-TAL segments that exhibited TUNEL-positivity were
classified as ‘apoptotic by fratricide’. *Po0.05.
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inflammation mediated by T lymphocytes and NK cells.
Specifically, for acute toxic renal failure, it is well accepted
that the course of this immune response involves p38
mitogen-activated protein kinase, interleukin-10, TNF-a,
and reactive oxygen species that in turn promote TNF-a
production. The pathophysiological and protective effects of
inhibiting these inflammatory key players have been demon-
strated in detail.15,21–24 Infiltrating NK cells and CD8þ T
lymphocytes induce apoptosis of tubular cells via the
Fas-FasL pathway by fusing secretory lysosomes with their
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plasma membrane, a process referred to as the ‘kiss of
death’.3,8 To further analyze the role of TNF family members
in CIN, we initially blocked the trimerization of FasL, which
is required for pro-apoptotic signaling. Because Karray
et al.25 showed a significant residual activity of FasL in
mutated gld-mice, we decided to use the previously
established monoclonal antibody MFL3 for the blockade of
FasL.26 The protective dose-dependent effect of MFL3 in
acute toxic renal failure (Figure 1g), however, could not help
to distinguish between tubular cell-expressed FasL and the
death factor on infiltrating immune cells. We used SCID/
beige mice to determine the in vivo relevance of T
lymphocytes and NK cells in toxic AKI. In line with the
report of Liu et al.,18 who investigated CD8- and CD4-
deficient mice, we demonstrated a protective effect against
CIN in SCID/beige mice, which cannot respond to danger
signals with a competent immune response. As shown in
Figure 2g, SCID/beige mice per se exhibited prolonged
survival from otherwise lethal CIN. Interestingly, cisplatin-
mediated acute renal failure also occurred in SCID/beige
mice, albeit delayed (Figure 2a–f) and with a lower mortality
rate than in C57/B6N wt mice. Complete protection from the
lethality of CIN, despite the SCID/beige phenotype, addi-
tionally requires a blockade of the Fas-FasL pathway (Figure 2g).
In detail, all wt mice died from CIN before day 5.5, and
SCID/beige mice died at the earliest at day 6.5. This result
may be interpreted as a deceleration of cell death in the
course of CIN byB4 days in immune-incompetent animals.
Additionally, immune cells appear to increase the intensity of
CIN because only 55.6% of SCID/beige mice died compared
with 100% of cisplatin-treated control animals (Po0.001).
However, from these experiments, we were unable to predict
which cells are involved in FasL-mediated renal failure in
immunodeficient SCID/beige mice.
We hypothesized that the source of FasL might be located
in the kidney itself because of the acute renal failure and
structural renal damage in SCID/beige mice after cisplatin
application, which can be blocked by MFL3. Therefore, we
tested freshly isolated, handpicked TAL segments in the
complete absence of immune cells. MFL3-sensitive TUNEL-
positivity after incubation with cisplatin hinted at a direct
functional involvement of FasL in these cells (Figure 3). To
analyze in detail whether tubular cells are capable of killing
each other, we induced apoptosis in freshly isolated primary
tubules taken from mice, a process that we know is mediated
by FasL. Interestingly, B23% of the nuclei in TAL segments
from GFP-transgenic mice proved to be apoptotic after 6 h of
co-incubation with the above mentioned PTCs (Figure 4).
The induction of apoptosis could be blocked by MFL3. In
analogy to the activation-induced cell death described, for
activated T lymphocytes, to terminate an immune response
and protect against autoimmunity, a process widely referred
to as ‘fratricide’, we transferred this term to renal tubular
cells. This is the first report that demonstrates that renal
tubular cells execute ‘fratricide’ on neighboring cells in acute
renal failure in vivo. Because of the well-defined preparation
of whole tubular segments, we show that tubular cells
themselves are sufficient to mediate FasL-dependent apop-
tosis in AKI in vivo. Our observations reveal an additional
mechanism that significantly contributes to organ failure
besides the infiltration of FasL-bearing immune cells into
the kidney.
Despite intensive research over decades, the pathophysiol-
ogy of acute renal failure is still only partially understood. In
this report, we contribute data showing acceleration and
deterioration by immune cells and a functional relevance of
tubular cell-expressed FasL to the understanding of the
pathophysiology of CIN. The knowledge of tubular cell
fratricide mediated through FasL may help to develop novel
strategies to improve the management of acute renal failure,
e.g., blocking apoptosis using bioengineered viral caspase-
inhibitors such as the fusion protein TAT-crmA.27 Specific
protein-based blockage of apoptosis might help to reduce
the severe side effects caused by cisplatin and to keep this
very effective chemotherapeutic agent as a future option for
clinicians and patients.
MATERIALS AND METHODS
Antibodies
The monoclonal IgG1 k hamster anti-mouse CD178 (FasL, CD95
ligand) antibody MFL3 was purchased from Bio Legend (San Diego,
CA, USA). Studies with MFL3 were performed with simultaneous
injection of cisplatin. Hamster IgG1 k isotype control monoclonal
antibodies were purchased from BD Biosciences (Heidelberg,
Germany) and applied in equimolar concentrations to MFL3.
Rabbit polyclonal anti-cleaved caspase-3 (Cell Signaling Technology,
Danvers, MA, USA) antibodies were used for immunohistochem-
istry (see below).
Preparation of drugs
Cisplatin was freshly prepared on each day of administration in PBS
at a concentration of 1mg/ml according to the standards for clinical
patient application.
Animals and drug administration
For all in vivo experiments, 6–8-week-old male C57/B6N mice
(Charles River, Sulzfeld, Germany), SCID/beige mice (CB17.B6-
Prkdcscid Lystbg/Crl; Charles River), and GFP-transgenic mice
(C57BL/6-Tg(CAG-EGFP)10sb/J; Charles River) with a weight of
20–22 g per mouse, were kept on a standard diet with freely available
water in our local animal facility under antigen-free conditions.
Mice were housed 4–5 per cage under a 12 h light and dark schedule
for at least 1 week before cisplatin administration. Acute kidney
failure was induced by i.p. application of 20mg cisplatin per kg body
weight. When mice in one group were treated with MFL3, the
control groups received PBS of equal volume as a second injection.
Blood samples were taken under anesthesia with 99% diethylether
(Roth, Karlsruhe, Germany) by retroorbital bleeding, and serum
levels of urea and creatinine were determined according to clinical
standards in the central laboratory of the University Hospital
Schleswig-Holstein, Campus Kiel, Germany, employing an enzy-
matic ultraviolet-test for urea (Hitachi Modular; Roche, Mannheim,
Germany) and an enzymatic peroxidase-dependent test for creati-
nine according to the manufacturer’s instructions (Hitachi Modular;
Roche). Kidneys were harvested directly after blood sampling and
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transferred to 4% neutrally buffered formalin for 12 h and then put
into 70% ethanol for pathological investigation. All experiments
were repeated in triplicate. In all figures, representative sections are
demonstrated.
Histology, immunohistochemistry, and morphological
assessment
Formaldehyde-fixed kidneys were dehydrated through graded
alcohol series and paraffinized. Paraffin sections of 3 to 8 mm were
stained with hematoxylin and eosin, and periodic acid-Schiff. Each
parameter was determined on at least eight different animals.
Immunohistochemical staining for activated caspase-3 was per-
formed using rabbit polyclonal anti-cleaved caspase-3 antibody (Cell
Signaling Technology), an indirect ABC-DAB technique (Vector
Laboratories, Burlingame, CA, USA) on heat-pretreated paraffin
sections as described earlier.28 Apoptotic tubular cells, identified by
nuclear positivity for cleaved caspase-3, were counted on 20
medium-power fields ( 200) in a blinded manner, and the mean
count per group was calculated from the means of each animal.
TUNEL assays were performed using the ‘In Situ Cell Detection Kit,
TMR red’ (Roche Diagnostic) according to the manufacturer’s
instructions. Nuclei were visualized using 40,6-diamidino-2-pheny-
lindole staining (Dianova, Hamburg, Germany). Kidney damage was
quantified by a pathologist in a double-blind manner, using a
previously described renal damage score.29 Briefly, tissues were
stained with hematoxylin and eosin, and periodic acid-Schiff, and
the degree of morphological involvement in renal failure was
determined using light microscopy. The following parameters were
chosen as indicative of morphological damage to the kidney after
cisplatin injection: brush border loss, red blood cell extravasation,
tubule dilatation, tubule degeneration, tubule necrosis, and tubular
cast formation. These parameters were evaluated on a scale of 0–4,
which ranged from not present (0), mild (1), moderate (2), severe
(3), to very severe (4). Each parameter was determined on at least
three different animals.
Isolation of murine primary tubular segments (PTCs)
and TAL segments
10-week-old male C57/B6N mice (Charles River) and GFP-transgenic
mice (C57BL/6-Tg(CAG-EGFP)10sb/J, Charles River) were anesthe-
tized by 4% isoflurane inhalation. Kidneys were perfused immedi-
ately with 1mg/ml collagenase type II (PAN Biotech, Aidenbach,
Germany) and 1mg/ml protease XIV (Roche Diagnostics) in 800ml
pre-warmed (37 1C) isolation buffer (140mmol/l NaCl, 0.4mmol/l
KH2PO4, 1.6mmol/l K2HPO4, 1mmol/l Mg2SO4, 10mmol/l Na-
acetate, 1mmol/l a-ketoglutarate, 1.3mmol/l Ca-gluconate, 5mmol/l
glycine, containing 48mg/l trypsin inhibitor and 25mg/l DNase I at
pH 7.4). Kidneys were subsequently removed, sliced, and incubated
in isolation buffer containing both enzymes for another 8min (37 1C,
800 r.p.m.). Isolated tubules were transferred on ice and after 5min of
sedimentation, they were washed with ice-cold isolation buffer to
remove enzymes and still-floating singular cells (visual control). This
unsorted tubular suspension constituted the primary tubular
segments (PTCs). Sorting of TAL segments according to their shape
and morphology was performed at 4 1C using a dissection
microscope (Leica MZ16, Wetzlar, Germany) in the presence of
1mg/ml albumin, as described previously.30 PTCs or sorted TAL
segments were divided into batches and transferred to the respective
experimental solutions. Incubation protocols were performed as
indicated and tubules were transferred to microscope slides through
cytospins.
Data management
Statistical significance was assessed using the two-sided Student’s
t-test for independent samples. Distribution fitting was performed
using the Kolmogorow–Smirnov Test. Differences were considered
significant if the P value was 0.05 or less, if not otherwise specified.
All experiments are representative of at least three independent
experiments. The number of animals included into each experi-
mental group (n) was assigned in every in vivo experiment.
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